PTAB Axes Patent Claims For Nektar Hemophilia Drug
The Patent Trial and Appeal Board has found that claims in two polymer patents that cover a hemophilia treatment developed by Nektar Therapeutics are obvious in light of a collection of...To view the full article, register now.
Already a subscriber? Click here to view full article